Precigen (PGEN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

PGEN Stock Forecast


Precigen stock forecast is as follows: an average price target of $6.00 (represents a 654.15% upside from PGEN’s last price of $0.80) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

PGEN Price Target


The average price target for Precigen (PGEN) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 654.15% upside from PGEN's last price of $0.80.

PGEN Analyst Ratings


Buy

According to 4 Wall Street analysts, Precigen's rating consensus is 'Buy'. The analyst rating breakdown for PGEN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Precigen Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 09, 2022-H.C. Wainwright$6.00$2.05192.68%654.15%
Row per page
Go to

The latest Precigen stock forecast, released on Aug 09, 2022 by H.C. Wainwright company, set a price target of $6.00, which represents a 192.68% increase from the stock price at the time of the forecast ($2.05), and a 654.15% increase from PGEN last price ($0.80).

Precigen Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.80$0.80$0.80
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Precigen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Precigen's last price of $0.80. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 15, 2024JMP SecuritiesMarket OutperformMarket OutperformHold
Aug 15, 2024H.C. WainwrightBuyBuyHold
Jun 03, 2024JMP SecuritiesUnderperformUnderperformHold
Jun 03, 2024Stifel NicolausMarket OutperformMarket OutperformHold
Nov 18, 2022Cantor Fitzgerald-OverweightInitialise
Nov 14, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Row per page
Go to

Precigen's last stock rating was published by JMP Securities on Aug 15, 2024. The company gave PGEN a "Market Outperform" rating, the same as its previous rate.

Precigen Financial Forecast


Precigen Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$16.72M$1.77M$1.85M$1.76M$16.72M$2.91M$32.02M$24.22M$21.56M$33.58M$24.51M$19.33M$23.58M$30.42M$29.84M$8.36M$23.04M$35.99M$23.34M$43.84M$53.75M
Avg Forecast$21.37M$5.23M$733.33K$733.33K$1.30M$931.40K$1.29M$1.48M$2.13M$1.60M$2.15M$2.23M$6.21M$2.72M$22.54M$28.32M$24.30M$20.94M$21.06M$24.00M$21.20M$17.70M$16.14M$10.50M$23.40M$33.00M$29.62M$32.12M$42.83M$49.61M
High Forecast$27.65M$6.77M$949.02K$933.33K$1.77M$1.21M$1.29M$1.92M$2.41M$2.07M$2.78M$2.88M$8.04M$2.72M$22.54M$28.32M$24.30M$20.94M$21.06M$24.00M$21.20M$17.70M$16.14M$10.50M$23.40M$33.00M$29.62M$32.12M$51.40M$59.54M
Low Forecast$15.71M$3.85M$539.22K$533.33K$827.27K$684.85K$1.29M$1.09M$1.85M$1.17M$1.58M$1.64M$4.57M$2.72M$22.54M$28.32M$24.30M$20.94M$21.06M$24.00M$21.20M$17.70M$16.14M$10.50M$23.40M$33.00M$29.62M$32.12M$34.27M$39.69M
# Analysts111221113111111111111010101099992015
Surprise %---------10.48%0.82%0.83%0.28%6.15%0.13%1.13%1.00%1.03%1.59%1.02%0.91%1.33%1.89%2.84%0.36%0.70%1.21%0.73%1.02%1.08%

Precigen's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.13M, with a low forecast of $1.85M, and a high forecast of $2.41M. PGEN's average Quarter revenue forecast represents a -87.27% decrease compared to the company's last Quarter revenue of $16.72M (Sep 23).

Precigen EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts111221113111111111111010101099992015
EBITDA---------$-7.64M$-18.55M$-22.46M$-19.81M$-3.13M$-20.22M$-13.47M$-57.60M$-21.63M$-11.92M$-9.31M$-33.23M$-20.80M$-34.10M$-46.56M$-157.82M$-43.65M$-28.82M$-50.40M$-37.59M$-24.35M
Avg Forecast$-19.20M$-4.70M$-658.80K$-658.80K$-1.17M$-836.74K$-1.16M$-15.01M$-1.91M$-1.43M$-1.93M$-16.05M$-1.56B$-2.48M$-20.58M$-17.17M$-22.19M$-19.12M$-19.23M$-12.04M$-19.36M$-16.16M$-14.73M$-27.74M$-21.37M$-30.13M$-27.04M$-37.80M$-36.71M$-22.32M
High Forecast$-14.11M$-3.46M$-484.41K$-479.13K$-743.19K$-615.25K$-1.16M$-12.01M$-1.66M$-1.05M$-1.42M$-12.84M$-1.25B$-2.48M$-20.58M$-13.73M$-22.19M$-19.12M$-19.23M$-9.63M$-19.36M$-16.16M$-14.73M$-22.19M$-21.37M$-30.13M$-27.04M$-30.24M$-29.37M$-17.86M
Low Forecast$-24.84M$-6.08M$-852.57K$-838.47K$-1.59M$-1.08M$-1.16M$-18.01M$-2.17M$-1.86M$-2.50M$-19.26M$-1.87B$-2.48M$-20.58M$-20.60M$-22.19M$-19.12M$-19.23M$-14.45M$-19.36M$-16.16M$-14.73M$-33.29M$-21.37M$-30.13M$-27.04M$-45.36M$-44.05M$-26.79M
Surprise %---------5.33%9.61%1.40%0.01%1.26%0.98%0.78%2.60%1.13%0.62%0.77%1.72%1.29%2.31%1.68%7.39%1.45%1.07%1.33%1.02%1.09%

undefined analysts predict PGEN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Precigen's previous annual EBITDA (undefined) of $NaN.

Precigen Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts111221113111111111111010101099992015
Net Income---------$87.38M$-20.32M$-22.73M$-22.18M$-7.64M$-26.06M$-19.25M$-25.35M$-29.76M$-20.05M$-17.32M$-41.66M$-29.51M$-43.35M$-56.00M$-169.22M$-53.63M$-38.77M$-60.71M$-41.99M$-31.40M
Avg Forecast$-2.52M$-12.62M$-15.14M$-14.30M$-12.40M$-21.77M$-24.15M$-20.71M$-15.26M$-20.19M$-25.37M$-22.15M$-1.61B$-34.07M$-36.59M$-23.69M$-30.28M$-37.01M$-31.34M$-22.41M$-42.90M$-35.33M$-34.07M$-33.37M$-62.20M$-60.57M$-74.45M$-45.53M$-41.00M$-28.78M
High Forecast$-1.66M$-8.28M$-9.93M$-8.94M$-10.92M$-14.28M$-15.84M$-16.57M$-13.08M$-13.24M$-16.64M$-17.72M$-1.29B$-34.07M$-36.59M$-18.95M$-30.28M$-37.01M$-31.34M$-17.92M$-42.90M$-35.33M$-34.07M$-26.69M$-62.20M$-60.57M$-74.45M$-36.43M$-32.80M$-23.03M
Low Forecast$-3.49M$-17.44M$-20.93M$-17.88M$-13.88M$-30.09M$-33.39M$-24.86M$-17.45M$-27.91M$-35.06M$-26.58M$-1.93B$-34.07M$-36.59M$-28.43M$-30.28M$-37.01M$-31.34M$-26.89M$-42.90M$-35.33M$-34.07M$-40.04M$-62.20M$-60.57M$-74.45M$-54.64M$-49.20M$-34.54M
Surprise %----------4.33%0.80%1.03%0.01%0.22%0.71%0.81%0.84%0.80%0.64%0.77%0.97%0.84%1.27%1.68%2.72%0.89%0.52%1.33%1.02%1.09%

Precigen's average Quarter net income forecast for Dec 23 is $-15.26M, with a range of $-17.45M to $-13.08M. PGEN's average Quarter net income forecast represents a -117.47% decrease compared to the company's last Quarter net income of $87.38M (Sep 23).

Precigen SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts111221113111111111111010101099992015
SG&A---------$10.14M$9.32M$11.64M$11.51M$10.14M$12.67M$19.58M$16.76M$18.66M$20.00M$18.70M$27.65M$22.30M$18.74M$23.02M$21.03M$24.74M$21.48M$33.59M$39.74M$35.14M
Avg Forecast$43.64M$10.69M$1.50M$1.50M$2.65M$1.90M$2.64M$3.02M$4.35M$3.26M$4.39M$4.54M$12.68M$5.56M$46.03M$24.09M$49.64M$42.77M$43.02M$49.02M$43.30M$36.16M$32.95M$21.44M$47.79M$67.40M$60.49M$25.20M$38.80M$32.21M
High Forecast$56.47M$13.83M$1.94M$1.91M$3.62M$2.46M$2.64M$3.91M$4.93M$4.22M$5.68M$5.88M$16.42M$5.56M$46.03M$28.91M$49.64M$42.77M$43.02M$49.02M$43.30M$36.16M$32.95M$21.44M$47.79M$67.40M$60.49M$30.23M$46.56M$38.65M
Low Forecast$32.09M$7.86M$1.10M$1.09M$1.69M$1.40M$2.64M$2.22M$3.77M$2.40M$3.23M$3.34M$9.33M$5.56M$46.03M$19.27M$49.64M$42.77M$43.02M$49.02M$43.30M$36.16M$32.95M$21.44M$47.79M$67.40M$60.49M$20.16M$31.04M$25.77M
Surprise %---------3.11%2.12%2.56%0.91%1.82%0.28%0.81%0.34%0.44%0.46%0.38%0.64%0.62%0.57%1.07%0.44%0.37%0.36%1.33%1.02%1.09%

Precigen's average Quarter SG&A projection for Dec 23 is $4.35M, based on 3 Wall Street analysts, with a range of $3.77M to $4.93M. The forecast indicates a -57.10% fall compared to PGEN last annual SG&A of $10.14M (Sep 23).

Precigen EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts111221113111111111111010101099992015
EPS----------$-0.08$-0.10$-0.11$-0.04$-0.13$-0.10$-0.13$-0.15$-0.10$-0.09$-0.23$-0.18$-0.26$-0.35$-1.09$-0.35$-0.25$-0.40$-0.33$-0.26
Avg Forecast$-0.01$-0.05$-0.06$-0.06$-0.05$-0.09$-0.10$-0.09$-0.06$-0.08$-0.10$-0.09$-0.10$-0.14$-0.14$-0.10$-0.12$-0.15$-0.12$-0.13$-0.17$-0.14$-0.14$-0.24$-0.25$-0.24$-0.29$-0.32$-0.19$-0.22
High Forecast$-0.01$-0.03$-0.04$-0.04$-0.04$-0.06$-0.06$-0.06$-0.05$-0.05$-0.07$-0.06$-0.07$-0.14$-0.14$-0.10$-0.12$-0.15$-0.12$-0.13$-0.17$-0.14$-0.14$-0.24$-0.25$-0.24$-0.29$-0.32$-0.15$-0.18
Low Forecast$-0.01$-0.07$-0.08$-0.07$-0.06$-0.12$-0.13$-0.12$-0.07$-0.11$-0.14$-0.13$-0.14$-0.14$-0.14$-0.10$-0.12$-0.15$-0.12$-0.13$-0.17$-0.14$-0.14$-0.24$-0.25$-0.24$-0.29$-0.32$-0.22$-0.26
Surprise %----------0.81%1.07%1.10%0.28%0.90%0.92%1.08%1.02%0.81%0.69%1.35%1.29%1.93%1.46%4.42%1.46%0.85%1.25%1.74%1.18%

According to undefined Wall Street analysts, Precigen's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PGEN previous annual EPS of $NaN (undefined).

Precigen Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PGENPrecigen$0.80$6.00650.00%Buy
ZNTLZentalis Pharmaceuticals$2.99$21.86631.10%Buy
SGMOSangamo Therapeutics$1.96$12.00512.24%Buy
INZYInozyme Pharma$2.81$14.67422.06%Buy
ADAPAdaptimmune Therapeutics$0.67$2.83322.39%Buy
IMMPImmutep$2.02$8.50320.79%Buy
AGENAgenus$2.57$8.00211.28%Hold
DAWNDay One Biopharmaceuticals$13.52$38.80186.98%Buy
AFMDAffimed$3.00$7.50150.00%Buy
SNDXSyndax Pharmaceuticals$15.77$34.30117.50%Buy
LPTXLeap Therapeutics$2.70$5.50103.70%Buy
EWTXEdgewise Therapeutics$31.51$45.0042.81%Buy
PTGXProtagonist Therapeutics$38.65$50.0029.37%Buy
CRVSCorvus Pharmaceuticals$8.40$10.6727.02%Buy
CRMDCorMedix$11.07$9.00-18.70%Buy

PGEN Forecast FAQ


Is Precigen a good buy?

Yes, according to 4 Wall Street analysts, Precigen (PGEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PGEN's total ratings.

What is PGEN's price target?

Precigen (PGEN) average price target is $6 with a range of $6 to $6, implying a 654.15% from its last price of $0.796. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Precigen stock go up soon?

According to Wall Street analysts' prediction for PGEN stock, the company can go up by 654.15% (from the last price of $0.796 to the average price target of $6), up by 654.15% based on the highest stock price target, and up by 654.15% based on the lowest stock price target.

Can Precigen stock reach $1?

PGEN's average twelve months analyst stock price target of $6 supports the claim that Precigen can reach $1 in the near future.

What are Precigen's analysts' financial forecasts?

Precigen's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5M (high $6.18M, low $3.89M), average EBITDA is $-18.172M (high $-14.525M, low $-21.845M), average net income is $-79.035M (high $-57.613M, low $-102M), average SG&A $10.22M (high $12.63M, low $7.95M), and average EPS is $-0.319 (high $-0.22, low $-0.428). PGEN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.07M (high $36.31M, low $20.63M), average EBITDA is $-25.214M (high $-18.534M, low $-32.616M), average net income is $-44.585M (high $-28.801M, low $-59.739M), average SG&A $57.32M (high $74.15M, low $42.14M), and average EPS is $-0.177 (high $-0.114, low $-0.237).

Did the PGEN's actual financial results beat the analysts' financial forecasts?

Based on Precigen's last annual report (Dec 2022), the company's revenue was $26.91M, which missed the average analysts forecast of $59.79M by -55.00%. Apple's EBITDA was $-72.072M, missing the average prediction of $-1.601B by -95.50%. The company's net income was $-79.777M, missing the average estimation of $-1.704B by -95.32%. Apple's SG&A was $48.01M, missing the average forecast of $88.36M by -45.67%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.485 by -17.53%. In terms of the last quarterly report (Sep 2023), Precigen's revenue was $16.72M, beating the average analysts' forecast of $1.6M by 947.88%. The company's EBITDA was $-7.644M, beating the average prediction of $-1.434M by 433.20%. Precigen's net income was $87.38M, missing the average estimation of $-20.189M by -532.80%. The company's SG&A was $10.14M, beating the average forecast of $3.26M by 211.04%. Lastly, the company's EPS was $0, missing the average prediction of $-0.08 by -100.00%